# US 2021/0332389 A1 · Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells using microcarriers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332389 A1
- Document ID: US20210332389A1
- Status: Published application
- Kind: A1
- Application number: 17/239,540
- Filed: 2021-04-23
- Published: 2021-10-28
- Earliest claimed: 2020-04-24
- Assignees: Inscripta, Inc.
- Applicants: Inscripta, Inc.
- Inventors: Phillip Belgrader; Nathan Bade; Christian Siltanen; Aamir Mir; Xi-Jun Chen; Janine Mok; Burak Dura; Bruce Chabansky; David Stumbo; Eric Smith; Jorge Bernate
- Web page: https://patentgrep.com/patent/US20210332389A1

## CPC

- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 15/1082: {Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors}
- B01L 3/502761: {specially adapted for handling suspended solids or molecules independently from the bulk fluid flow, e.g. for trapping or sorting beads or physically stretching molecules}
- B01L 3/502769: {characterised by multiphase flow arrangements}
- B01L 7/00: Heating or cooling apparatus (autoclaves B01J3/04); Heat insulating devices
- C12M 23/12: {Well or multiwell plates (C12M25/04 takes precedence)}
- C12M 23/16: {Microfluidic devices; Capillary tubes (integrated microfluidic structures B01L3/5027; microreactors B01J19/0093)}
- C12M 23/42: {Integrated assemblies, e.g. cassettes or cartridges}
- C12M 23/50: {Means for positioning or orientating the apparatus (C12M41/08 takes precedence)}
- C12M 25/16: {Particles; Beads; Granular material; Encapsulation (chemical or physical processes conducted in the presence of fluids and solid particles B01J8/00)}
- C12M 27/10: {Rotating vessel}
- C12M 29/04: {Filters; Permeable or porous membranes or plates, e.g. dialysis}
- C12M 33/14: {with filters, sieves or membranes}
- C12M 35/08: {Chemical, biochemical or biological means, e.g. plasma jet, co-culture}
- C12M 41/36: {of biomass, e.g. colony counters or by turbidity measurements (electrooptical investigation of individual particles G01N15/14, flow cytometers G01N15/1404)}
- C12M 43/00: {Combinations of bioreactors or fermenters with other apparatus}
- C12M 47/02: {Separating microorganisms from the culture medium; Concentration of biomass (separating microorganisms from their culture media C12N1/02)}
- C12M 47/04: {Cell isolation or sorting (purging biological preparations of unwanted cells C12N5/0081, determining the presence or kind of microorganism C12Q1/04)}
- C12N 5/0696: {Artificially induced pluripotent stem cells, e.g. iPS}
- C12N 9/222: {Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes}
- C12N 15/1065: {Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags}
- C12N 15/1068: {Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/86: Viral vectors
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- C12N 15/90: Stable introduction of foreign DNA into chromosome
- C12N 15/907: {in mammalian cells}
- B01L 2200/0647: Handling flowable solids, e.g. microscopic beads, cells, particles
- B01L 2300/0681: Filter
- B01L 2300/123: Flexible; Elastomeric
- B01L 2300/161: Control and use of surface tension forces, e.g. hydrophobic, hydrophilic
- B01L 2400/0415: electrical forces, e.g. electrokinetic
- B01L 2400/0421: electrophoretic flow
- B01L 2400/0424: Dielectrophoretic forces
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2510/00: Genetically modified cells
- C12N 2740/10011: Retroviridae
- C12N 2740/15011: Lentivirus, not HIV, e.g. FIV, SIV
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N 2750/14111: Dependovirus, e.g. adenoassociated viruses
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- B01L: CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- C12M: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; {APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS}

## Abstract

This invention relates to compositions of matter, methods, modules and automated, end-to-end closed instruments for automated mammalian cell growth, reagent bundle creation and mammalian cell transfection followed by nucleic acid-guided nuclease editing in live mammalian cells.

## Claims

### Claim 1

A method for transfecting and performing nucleic acid-guided nuclease editing in mammalian cells in an automated closed cell editing instrument comprising the steps of comprising the steps of:
synthesizing a library of editing cassettes off instrument, wherein each editing cassette comprises a different gRNA and donor DNA pair;
amplifying each editing cassette in the library of editing cassettes in a partition separate from other editing cassettes;
adding nuclease to each partition with an amplified editing cassette;
adding lipofectamine to each amplified editing cassette and nuclease to form a library of lipofectamine/nucleic acid/nuclease complexes;
adding microcarriers to each lipofectamine/nucleic acid/nuclease complex in the library of lipofectamine/nucleic acid/nuclease complexes, wherein the microcarriers are coated in extracellular matrix or a cell adhesion molecule coating and wherein the lipofectamine/nucleic acid/nuclease complexes bind to the microcarriers;
transferring cell growth medium, the microcarriers and mammalian cells to a growth module in the automated closed cell editing instrument via a liquid handling system;
allowing the cells to seed on the coated microcarriers in the growth module;
providing conditions for the cells to take-up the lipofectamine/nucleic acid/nuclease payloads in the growth module;
providing conditions for the nucleic acids and nuclease to edit the cells in the growth module; and
detaching the edited cells from the microcarriers.

### Claim 2 (depends on 1)

The method of claim 1, wherein the growth module is a rotating growth module.

### Claim 3 (depends on 1)

The method of claim 1, wherein the growth module is a tangential flow filtration module.

### Claim 4 (depends on 1)

The method of claim 1, wherein the growth module is a bioreactor.

### Claim 5 (depends on 1)

The method of claim 1, wherein the liquid handling system comprises an air displacement pipettor.

### Claim 6 (depends on 5)

The method of claim 5, wherein the automated closed cell editing instrument comprises a reagent cartridge.

### Claim 7 (depends on 1)

The method of claim 1, wherein the liquid handing system comprises a manifold with one or more connections to the bioreactor.

### Claim 8 (depends on 1)

The method of claim 1, wherein the liquid handling system comprises reagent receptacles individually connected to the growth module.

### Claim 9 (depends on 1)

The method of claim 1, wherein the mammalian cells are iPSCs.

### Claim 10 (depends on 1)

The method of claim 1, wherein the mammalian cells are primary cells.

### Claim 11 (depends on 1)

The method of claim 1, wherein the microcarriers are fabricated from natural organic materials, biocompatible synthetic polymers, or inorganic materials.

### Claim 12 (depends on 11)

The method of claim 11, wherein the microcarriers are fabricated from polystyrene.

### Claim 13 (depends on 11)

The method of claim 11, wherein the microcarriers are fabricated from a polyacrylate.

### Claim 14 (depends on 11)

The method of claim 11, wherein the microcarriers are coated with laminin.

### Claim 15 (depends on 14)

The method of claim 14, wherein the microcarriers are coated with laminin L-521.

### Claim 16 (depends on 1)

The method of claim 1, wherein the microcarriers range in size from 30-1200 microns in diameter.

### Claim 17 (depends on 16)

The method of claim 16, wherein the microcarriers range in size from 50-150 microns in diameter.

### Claim 18 (depends on 1)

The method of claim 1, between the enriching and second delivering step, the mammalian cells are detached from the microcarriers, the medium is exchanged and fresh microcarriers are added to the growth module.

### Claim 19 (depends on 18)

The method of claim 18, wherein the growth module is a rotating growth module and the mammalian cells are detached from the microcarriers by increasing rotation of the rotating growth vial.

### Claim 20 (depends on 19)

The method of claim 19, wherein the growth module is a rotating growth module comprising fins, wherein the fins comprise frits.

### Claim 21 (depends on 18)

The method of claim 18, wherein the growth module is a tangential flow filtration module and the mammalian cells are detached from the microcarriers by bubbling.

### Claim 22 (depends on 18)

The method of claim 18, wherein the growth module is a tangential flow filtration module and the mammalian cells are detached from the microcarriers by passing the mammalian cells through a conduit between reservoirs, wherein the conduit comprises at least one frit.

### Claim 23 (depends on 18)

The method of claim 18, wherein the growth module is a bioreactor with at least one impeller and the mammalian cells are detached from the microcarriers by increasing revolutions per minute of the at least one impeller.

### Claim 24 (depends on 18)

The method of claim 18, wherein the growth module is a bioreactor with at least two impellers and the mammalian cells are detached from the microcarriers by increasing revolutions per minute of the at least two impellers.

### Claim 25 (depends on 1)

The method of claim 1, wherein the nuclease is provided as a protein.

### Claim 26 (depends on 1)

The method of claim 1, wherein the nuclease is provided as a nucleic acid coding sequence under the control of a promoter.

### Claim 27 (depends on 1)

The method of claim 1, wherein each different editing cassette in the library of editing cassettes comprises a different barcode.

### Claim 28 (depends on 1)

The method of claim 1, wherein the steps of providing conditions for the cells to take-up the lipofectamine/nucleic acid/nuclease payloads in the growth module and providing conditions for the nucleic acids and nuclease to edit the cells in the growth module may take up to 2 days.

### Claim 29 (depends on 28)

The method of claim 28, wherein the steps of providing conditions for the cells to take-up the lipofectamine/nucleic acid/nuclease payloads in the growth module and providing conditions for the nucleic acids and nuclease to edit the cells in the growth module may take up to 24 hours.

### Claim 30 (depends on 1)

The method of claim 1, wherein the editing cassettes comprise from 5′ to 3′: a first primer binding region; a spacer region of the gRNA; a scaffold region of the gRNA; the donor DNA; a barcode; a second primer binding region; and a third primer binding region.
